Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration

Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity

Lead sponsor: Sanofi•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Related studies

COMPLETEDPhase 1/2

Stem Cell Therapy for Outer Retinal Degenerations

NCT02903576 · Age Related Macular Degeneration, Stargardt's Disease, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 12, 2025Terms

Trial snapshot

StatusACTIVE_NOT_RECRUITING

PhasePHASE2

Enrollment27

Start dateDec 2012

Last updatedJun 12, 2025

Condition

Stargardt's Disease

Locations shown

Oregon Health and Science University Site Number : 840001

Portland, Oregon

Investigational Site Number : 250001

Paris

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 12, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions